A total of 403 healthy, premenopausal women, residing near Santa Clara, California, were recruited from a large health care plan in California for a study of menstrual function. After a telephone interview, participants collected daily urine samples and recorded bleeding and other information in diaries. Data were collected during 1990-1991. Urine samples were analyzed for creatinine and for estradiol and progesterone metabolites by enzyme-linked immunoassay. Computer algorithms were developed to derive menstrual segment length, ovulatory status, day of ovulation, and other parameters from the urine and diary data. (We use "segment" rather than "cycle" to avoid implying that normal cycling occurred.) The average length of participation was 141 (standard deviation, 45) days. The mean segment length was 28.8 (standard deviation, 4.4) days; follicular phase length, 16.0 (standard deviation, 4.4) days; and luteal phase length, 12.9 (standard deviation, 1.7) days; 19 (4.7%) women experienced anovulatory episodes. In exploratory multivariate analyses, important associations included the following: age of >35 years with decreased segment and follicular phase lengths; heavier weight (upper quartile) with anovulation and increased follicular phase and decreased luteal phase lengths; Hispanic ethnicity with anovulation and increased segment length; and past difficulty in achieving pregnancy with anovulation and increased length and variability of segments and follicular phases. Urine biomarkers can be used successfully to evaluate menstrual function in epidemiologic studies. Am J Epidemiol 1998; 147: 1071-80.
metabolites of sex steroid hormones allows subtle differences in menstrual function to be examined noninvasively (5) (6) (7) (8) .
The Women's Reproductive Health Study was designed to use urine biomarkers to explore the relation of a variety of environmental and lifestyle exposures to menstrual function in a relatively large populationbased sample of healthy premenopausal women. This paper describes the methods used to collect and process the samples and the algorithms developed to characterize menstrual segments. In addition, the study population is characterized in terms of menstrual parameters, and associations between basic demographic and reproductive factors and menstrual parameters are explored.
MATERIALS AND METHODS

Subjects
All female members of the Kaiser Permanente Medical Care Program, 18-39 years of age, married, and who had residential zipcodes located within approximately 10 miles (16 km) of the study's field office in Santa Clara, California, were mailed recruitment in-formation and later screened by telephone. Eligibility criteria (see below) were intended to select women at some risk for pregnancy, since another goal was to examine pregnancy-related outcomes. Women were offered a payment of $50 upon successful completion of the study. The study protocol was approved by the institutional review boards of Kaiser Permanente and the California Department of Health Services.
Of 10,299 women identified from Kaiser membership rolls, we were unable to contact 23.9 percent, 7.4 percent did not speak English, and 5.8 percent refused screening. Of the 6,481 women successfully screened, 83.2 percent were ineligible (using oral contraceptives or intrauterine devices or they or their partner had been surgically sterilized, 53.2 percent; no longer a member of the health plan, 12.8 percent; pregnant or last menses >6 weeks ago, 12.1 percent; not pregnant after 3 months of unprotected intercourse, 9.9 percent; not married, 7.7 percent; other, 4.3 percent). Of the 1,092 eligible women, 553 agreed to begin the study, but 89 dropped out during urine collection and 61 became ineligible (e.g., because of separation from husband or beginning oral contraceptives). This left a total of 403 women who completed the study. Eight women with tubal ligations (included in the ineligible group above) also participated in the study to serve as controls for pregnancy-related analyses. They are not included in any analyses presented here.
Data collection
Information on demographics, previous reproductive history, lifestyle factors, and selected environmental exposures was obtained from a baseline telephone interview completed by all Women's Reproductive Health Study participants. In addition, each woman was instructed to collect and freeze a sample of first morning urine every day. Samples were regularly retrieved by field workers from the Women's Reproductive Health Study and shipped to the University of California, Davis. Concurrent with urine collection, participants recorded the amount of vaginal bleeding (number of pads or tampons used/day) and other information in a diary. Women who collected daily urine samples for at least 60 days, through two menstrual periods, or until a clinically recognized pregnancy occurred were considered to have successfully completed the study. Data were collected during 1990-1991.
Laboratory analysis
Each urine sample was analyzed for creatinine and for the progesterone metabolite pregnanediol-3-glucuronide (PdG) and the estradiol metabolites estrone sulfate and estrone glucuronide (together referred to as E1C) by enzyme-linked immunoassay (6) . PdG and E1C were set to missing if the urine sample was very dilute (<0.2 mg of creatinine per ml) or if the values were extremely high (PdG > 25 /ig/ml or E1C > 250 ng/ml). Hormone values below the assays' minimum detection limits (PdG < 0.15 fi-g/ml or E1C < 7.8 ng/ml) were set to the minimum detection limits. PdG and E1C values were then divided by the creatinine measurement to adjust for variations in urine volume. We graphed each participant's daily creatinine-adjusted hormone values (referred to as creatinine-adjusted pregnanediol-3-glucuronide (APdG) and creatinine-adjusted estrone conjugates), as well as bleeding data from her diary, to allow visual examination of patterns.
Definition of menstrual segments
Participants were instructed to affix a red sticker to the first urine sample collected after the beginning of what they thought was a menstrual period, and this was generally considered to be the first day of a menstrual segment. (We reserve the term "cycle" for a segment displaying the standard cyclical pattern, i.e., an ovulatory segment bounded by bleeding associated with a drop in luteal APdG.) Since a woman may have begun bleeding after collecting the day's urine sample, segment start dates were adjusted 1 day earlier if a woman reported bleeding on her diary (>1 pad/day) on the day before the flagged sample. In four segments where the cyclical APdG pattern (a flat baseline followed by a luteal surge) was repeated twice, we split the segment into two where the first APdG surge returned to baseline; we also adjusted ten segment breaks in five women to correspond to the onset of main menstrual bleeding.
Determination of ovulatory status and probable day of ovulation
Ovulatory status was determined for all segments using an approach modeled on that developed by Kassam et al. (9) . Within each segment, rolling 5-day averages of APdG (APdG5) were calculated. The minimum APdG5 preceding the maximum APdG5 was designated as the segment baseline. An ovulation threshold was calculated as follows: (baseline + 1 + Vbaseline). This modification of the threshold of Kassam et al. of three times the baseline improved performance in segments with lower or higher than average APdG baselines. In segments with a typical APdG baseline of ~ 1 /ig of creatinine per mg, the two thresholds correspond closely. A segment was defined as ovulatory if both the maximum APdG5 and at least three of the five APdG values constituting that average exceeded the ovulation threshold. A segment was considered nonovulatory if the maximum APdG5 was £ (baseline + \A>aseline) and if <30 percent of urine samples from the "midsegment" (from day 6 to the sixth day from the end) were missing. Segments that did not meet the criteria for ovulation or nonovulation were considered questionable segments.
In ovulatory and questionable segments, the day of ovulation was estimated using a modification of an algorithm created by Baird et al. (10) . Generally, the Baird algorithm picks the day after the sharpest and tallest ElC:PdG peak within a segment as the probable day of ovulation. This method has been found to correlate well with methods based on urine luteinizing hormone levels (10) . We modified the Baird algorithm slightly to allow the algorithm to perform more efficiently in our data set. First, we estimated EIC and/or PdG values for single missing days by simple linear interpolation. In addition, because our data set contained more very low PdG values than did the data set used to develop the Baird algorithm, we calculated the ElC:(PdG + 1) ratio instead of the ElC:PdG ratio. Although the general shape of the ElC:PdG curve is retained, using PdG + 1 causes it to flatten, and there tend to be fewer peaks in the ratio within a segment. Consequent to these effects we made two additional modifications: 1) ratio peaks containing a day of ovulation had to have EIC:(PdG +1) values 3 and 4 days after the peak that were £60 percent of the peak ratio value; 2) the ratio peak with the highest "shoulders" (the average of the ratio values for the day before and after the peak) was always chosen as the peak containing the day of ovulation.
Our modified algorithm was validated in an independent data set of 69 menstrual segments that included serum and/or urine luteinizing hormone measurements in addition to EIC and PdG. A day of ovulation that was within ± 1 day of the luteinizing hormone peak was selected by our modified algorithm in 84 percent of the segments and by the unmodified Baird algorithm in 77 percent of the segments. In our own data set, use of the modified algorithm identified a day of ovulation in 92.5 percent of ovulatory segments compared with 78.7 percent using the original Baird algorithm. The estimates were within 2 days of each other in 88.8 percent of ovulatory segments where both algorithms chose a day of ovulation.
Verification of results
Repeat laboratory analysis of a sample of 146 segments indicated that abnormal-appearing hormone patterns frequently appeared normal on reassay. Within this sample, 69 percent of nonovulatory segments were designated ovulatory on reassay, and 41 percent of ovulatory segments with an "abnormal" day of ovulation (defined at this preliminary stage as resulting in a follicular phase of ^20 days or a luteal phase of £10 days) were "normal" on reassay. It was subsequently discovered that in some samples PdG had precipitated prior to assay. Since costs prohibited duplicate analyses of all segments, and since over 90 percent of ovulatory segments with a "normal" day of ovulation were unchanged on reassay, we chose to reassay all nonovulatory segments and all segments with an "abnormal" day of ovulation. Of a total of 2,240 segments, 533 potentially abnormal segments were reanalyzed; of these, the abnormal pattern was confirmed in 243 (45.6 percent). In reassayed segments with discordant results, the more "normal" assay results were used.
After the incorporation of reassay data, all hormone graphs were inspected, and manual changes were made to ovulation status and day of ovulation where appropriate. Twenty-two segments (20 questionables and two where the algorithm failed to calculate ovulation status) were recoded as ovulatory and assigned a day of ovulation, since in these segments a distinct though small luteal rise in APdG could be discerned. Another questionable segment was recoded to nonovulatory. Twelve segments, determined by the algorithm to be ovulatory but displaying erratic APdG values, were recoded to questionable. Additional manual changes included selection of a day of ovulation for 33 segments where the algorithm had been unable to calculate one. In 12 ovulatory segments with missing data on crucial days, we manually set the day of ovulation to missing. Finally, we moved the day of ovulation of an additional 45 segments to correspond better with the creatinine-adjusted estrone conjugates' peak and rise in APdG. After the completion of data cleaning, reassaying, and manual recoding, 1,838 segments (82.1 percent) had their ovulatory status and day of ovulation determined by the original assays, 277 (12.4 percent) used data from reassays to calculate these parameters, and 125 (5.6 percent) had at least one parameter that had been altered manually.
Menstrual segment-based outcomes
We defined three menstrual segment-based outcomes: segment length, follicular phase length, and luteal phase length. Segment length was defined as the number of days from one segment start date to the next. Follicular phase length was defined as the number of days from the segment start date up to and including the day of ovulation. Luteal phase length was calculated as the difference between the segment length and follicular phase length.
We restricted analysis of each outcome to segments with reasonably reliable information. For analyses of segment length, we excluded "partial first segments" (urine collection beginning >14 days after the selfreported onset of the last menstrual bleed), last segments of unknown length, and the segments from one woman whose segment start dates appeared to have no correlation with her hormones and who did not complete her diary. Excluded from analyses of follicular phase and luteal phase lengths were segments where the day of ovulation was missing or likely to be inaccurate, that is, nonovulatory and questionable segments, segments missing ^30 percent of urine from the midsegment, and 14 segments from six participants whom we suspected of filling several vials with urine from a single day. (These segments were identified by examining graphs for instances where creatinine, E1C, and PdG levels would plateau for several days and then all change simultaneously.) In addition, analyses of follicular phase length excluded partial first segments, and analyses of luteal phase length excluded last segments of unknown length and segments in which a clinically recognized pregnancy occurred.
Woman-based outcomes
We analyzed anovulation at the woman level, rather than at the segment level, because upon examining the graphs it was apparent that a single anovulatory episode could contain several or no nonovulatory segments depending on whether or not the participant had any breakthrough bleeding and if the bleeding was considered to be a menstrual period. In addition, a few women perceived midcycle spotting as menstrual bleeding, erroneously splitting an ovulatory cycle into a short nonovulatory segment and a segment with little or no follicular phase. Anovulation at the woman level was thus defined as a period of ^36 days with no significant rise in APdG (35 days was the 95th percentile for segment length in our data). This included the following: 1) consecutive nonovulatory segments summing to ^36 days; 2) a nonovulatory segment plus the follicular phase of the next segment summing to S36 days; 3) a follicular phase >36 days; and/or 4) a partial segment with >36 days of urine collection and no APdG5 > (baseline + Vbaseline). Seven women who had shorter periods without ovulation but who, had it not been for missing data, may also have met these criteria were considered to be possibly anovulatory.
We also calculated within-woman standard deviations of segment length, follicular phase length, and luteal phase length for women with three or more eligible segments.
Statistical analysis
Means and percentiles were calculated for all segmentbased outcomes. Since these outcomes are often correlated within-woman, and since women with short segments may be able to contribute more segments (11), we also used a bootstrap process to adjust distribution statistics for the number of segments collected per woman. To do this, means and percentiles were calculated using a single eligible segment randomly selected from each woman. The means of these means and percentiles over 100 iterations constitute the adjusted distribution statistics. We also generated distribution statistics for the subset of women who cycled consistently, excluding 53 participants with anovulatory or possibly anovulatory episodes, nonovulatory or questionable segments, bleeding throughout a segment, false segments, or segments where the APdG dropped to baseline at least 3 days before the onset of reported bleeding.
Exploratory bivariate and multivariate analyses of segment-based outcomes were performed by linear regression, controlling for repeated measures withinwoman (SAS PROC MIXED with the REPEATED (CS) option; SAS Institute, Inc., Cary, NC). No adjustments were made for multiple comparisons (12) . Multivariate analyses of risk factors for anovulation were done by multiple logistic regression, with the number of days of study participation as a covariate (excluding segments with missing or questionable ovulatory status and the days after ovulation in segments in which a clinically recognized pregnancy occurred). Thirty-one women with less than 36 study participation days and the seven possibly anovulatory women were excluded from analyses of anovulation. The means of within-woman standard deviations of segment length, follicular phase length, and luteal phase length in various demographic and reproductive subgroups were compared using regression techniques. Multivariate analyses of within-woman variability controlled for the number of eligible segments collected per woman.
RESULTS
General characterization of cohort
Characteristics of the study cohort are presented in table 1. The mean age was 31 (standard deviation, 4.2; range, 21-39) years, and participants were predominantly white, well educated, and parous. The average participant contributed 5.6 segments and collected urine on over 95 percent of study days (table 2). 
Descriptive statistics of outcomes
Distribution characteristics of segment length, follicular phase length, and luteal phase length are described in table 3. Luteal phase length was less variable than segment length or follicular phase length. Segment length and follicular phase length, but not luteal phase length, had skewed distributions with long right tails. Using the bootstrap technique to minimize bias due to number of segments collected per woman resulted in slightly higher means of segment length and follicular phase length but had no effect on luteal phase length. Restricting the analysis to cycles brought in the extremes of the distributions but had little impact on measures of central tendency for any of the outcomes.
We used the unadjusted fifth and 95th percentiles of segment length to define short and long segments and to determine the proportion of women who had experienced at least one of these (table 4) . Similarly, we used the 95th percentile of follicular phase length to identify women with at least one segment with delayed ovulation and the fifth percentile to identify women with at least one short luteal phase segment. The average within-woman standard deviation in segment length was 2.4 (standard deviation, 1.8; range, 0-14.5) days; the average within-woman standard deviation in follicular phase length was 2.2 (standard deviation, 1.6; range, 0.5-13.1) days; and the average withinwoman standard deviation in luteal phase length was 1.2 (standard deviation, 0.8; range, 0-9.3) days.
Relations between outcomes
Over 84 percent of the variance in segment length was due to variation in follicular phase length; conversely, only 3 percent of the variance in segment length was due to variation in luteal phase length (analysis of variance R 2 s). Compared with women who had no anovulatory episodes, anovulatory women experienced markedly longer segments (mean, 39.9 vs. 28.8 days; 95 percent confidence interval for difference 9.2-12.9 days) and longer follicular phases (mean, 28.9 vs. 16.1 days; 95 percent confidence interval for difference 10.9-14.8 days). No difference was seen between anovulatory and ovulatory women in mean luteal phase length (12.6 vs. 12.9 days; 95 percent confidence interval for difference -1.1 to 0.4). Anovulatory women also displayed more variation in all segment-based outcomes than did women with no anovulatory episodes (segment length: mean within-woman standard deviation, 6.8 vs. 2.2, p < 0.01; follicular phase length: mean within-woman standard deviation, 7.0 vs. 2.1, p -0.08; luteal phase length: mean within-woman standard deviation, 1.8 vs. 1.2, p = 0.05). 
Exploratory analysis of outcomes with demographic and reproductive factors
In a multivariate analysis that controlled for all covariates simultaneously (table 5), mean segment length and follicular phase length appeared to decrease with age, especially after age 34. Weight in the upper quartile was strongly associated with shorter luteal phases and longer follicular phases. Substituting body mass index for weight and height attenuated these findings. Hispanic and Asian women had segment lengths and follicular phases that were on average almost 2 days longer than women of other ethnic backgrounds. Women who reported having had difficulty becoming pregnant were also more likely to have longer segment lengths and follicular phases. Conversely, women with a high school degree or less had segment lengths and follicular phases that were on average a day shorter than those of more educated women. Other associations significant at thep < 0.10 level included slightly shorter luteal phase lengths among women with a history of sexually transmitted disease or past use of an intrauterine device and longer follicular phase lengths among women who had used oral contraceptives in the past.
The direction and magnitude of differences in means were generally preserved when the analysis was restricted to women who cycled consistently. However, for women with a high school education or less and for women with self-reported difficulty in achieving pregnancy, differences from the reference means diminished.
The relations between anovulation and demographic and reproductive characteristics are described in table 6. Age appeared to have no impact on the risk of anovulation. Women in both the lowest and highest quartiles of weight were at least three times more likely to be anovulatory than women in the midrange. As with the segment-based outcomes, substituting body mass index for weight and height resulted in lower odds ratios for the outer quartiles. Hispanics appeared to be at increased risk for anovulation, and the association became stronger after adjustment for other demographic and reproductive factors. A low educational level was associated with decreased risk for anovulation; only one of 90 women in this subgroup was anovulatory. In the unadjusted analysis, women with at least one prior spontaneous abortion were more likely to be anovulatory than women with none, but this association diminished after adjustment for other factors. Difficulty in achieving pregnancy, however, remained a strong predictor for anovulation after adjustment. A history of uterine fibroids was also associated with elevated risk for anovulation.
Within-woman variation appeared to vary little with demographic or reproductive factors, except that women less than 30 years of age and women with past difficulty in achieving pregnancy had slightly more variation in segment and foliicular phase lengths than other women (table 7) . The finding for women with past difficulty in achieving pregnancy remained when analyses were restricted to women who cycled consistently.
DISCUSSION
Using urine biomarkers to study menstrual function was successful. Over 400 women were compliant with urine collection, and the detailed data obtained allowed us to examine foliicular and luteal phases, differentiate cycles from noncycle segments, and identify anovulatory episodes. Despite the demands involved, 37 percent of initially eligible women enrolled in and completed the study. Development of less onerous methods of sample collection and storage (e.g., using filter paper instead of vials) may increase participation rates in future studies. Planning for duplicate assays of all samples would have been more efficient than identifying and reassaying only abnormal segments. In addition, instructing participants to begin and end urine collection with menstrual bleeds would have minimized the number of segments with missing outcomes. Anovulation was uncommon in our cohort, occurring in less than 5 percent of women. The proportion of segments that were nonovulatory (1 percent) was similar to that in another study with daily urine measurements (13), although it was somewhat less than that found in studies using basal body temperatures or weekly urine measurements (14-17, reviewed in reference 18). Outcomes such as long segments, delayed ovulation, and short luteal phases were considerably more common than anovulation in our cohort. The means and ranges of follicular and luteal phase lengths in this study were similar to those reported by Baird et al. (13) , but the mean follicular phase length was 1-2 days shorter than that reported by two studies that used basal body temperatures (14, 15) . Means and medians of segment length were comparable with those previously reported (14, (19) (20) (21) (22) . Although our cohort was population based, eligibility criteria and the low overall participation rate limit the generalizability of these findings. For example, the prevalence of menstrual disturbances may have been underestimated as amenorrheic women were ineligible. Conversely, overestimates may have occurred if women concerned about their menstrual function were more willing to participate than women without such concerns.
We identified several intriguing relations between menstrual function and demographic and reproductive characteristics. Our finding that older women tended to have shorter and less variable segments is consistent with observations from previous studies (14, 19, 23) . The somewhat longer cycle lengths reported in the paper by Gold et al. (23) may have been a reflection of the ethnic diversity of their cohort, as we found that Hispanics and Asians had significantly longer segment lengths than other ethnic groups. The relation between body weight or mass and various menstrual abnormalities has been reported by others (22) (23) (24) (25) . Other than for age and weight, there has been little previous research into the determinants of variability in menstrual function (18) . Thus, many of the associations noted in this report await confirmation.
Menstrual outcomes are interesting endpoints in and of themselves; they may also prove to be intervening factors or markers for other adverse health outcomes. For example, the strong association of past fertility problems with anovulation and long follicular phases suggests that these menstrual characteristics may be associated with poor future reproductive performance as well. Further study of menstrual cycle parameters may also help in understanding the mechanisms that link personal characteristics and lifestyle and environmental exposures to such diseases as osteoporosis and reproductive cancers (18) .
In summary, urine biomarkers can be successfully used to evaluate menstrual function in epidemiologic studies. We encourage other researchers to confirm our findings and to use these techniques to further explore subtle reproductive effects of lifestyle and environmental exposures.
